<DOC>
	<DOCNO>NCT00507754</DOCNO>
	<brief_summary>Primary Objective : 1 . To evaluate performance new T-SPOT.TB test conventional TST screen Latent Tuberculosis infection patient cancer undergo Hematopoietic Stem Cell Transplant . Secondary Objectives : 1 . To examine factor associate positive response T-SPOT.TB TST ( tuberculin skin test ) patient anergy . 2 . To determine impact immunosuppressive antineoplastic therapy screen performance T-SPOT.TB TST cancer patient .</brief_summary>
	<brief_title>Latent Tuberculosis Infection Cancer Patients</brief_title>
	<detailed_description>TB AND TB TESTS : Patients cancer consider `` immunocompromised . '' This mean , cancer cancer treatment , immune system function normally , decrease ability fight infection disease . This immunocompromised condition place patient ( probably contact TB bacteria , result latent , inactive , TB ) risk active TB . Latent TB cause symptom sign active TB infection . It important identify patient risk develop active TB , receive timely treatment TB . The Tuberculin skin test ( TST ) currently use detect latent TB . The TST consider low detection sensitivity , mean may always detect latent TB , may turn active TB infection . The T-SPOT.TB new test researcher want study see whether may effective accurate TST identify patient risk develop active TB . STUDY PARTICIPATION : If agree take part study , follow test do step take . - You extra blood ( 1 2 teaspoon ) drawn . It do time routine clinic visit M. D. Anderson regular blood draw already admit hospital . This blood use perform T-SPOT . TB test . If TST ( tuberculin skin test ) perform M. D. Anderson past 45 day , may probably necessary repeat TST . However , research staff decide need new TST . You may TST perform blood drawn . In case , rest 10 minute blood draw . - You receive fluid call tuberculin order TST perform . Tuberculin inject beneath surface skin forearm . You see small raise area skin injection give . This reaction wear day . - After 2-3 day ( 48-72 hour later ) , return M. D. Anderson ( hospital ) , health care professional look measure swell redness site TST . The doctor learn TST result positive negative . If TST positive study doctor discus , primary doctor evaluation treatment . Although informed TST result , inform T-SPOT . TB test result T-SPOT . TB test use investigational purpose study use diagnostic purpose . The study doctor use result T-SPOT . TB test make research comparison TST test result . LENGTH OF STUDY : Your participation study TB test perform TST check health care professional . This investigational study . The TST FDA approve commercially available . The T-SPOT.TB test FDA approve commercially available . It authorize use research . Up 200 patient take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Latent Tuberculosis</mesh_term>
	<criteria>Males female . Patients receive chemotherapy hematologic malignancy solidorgan cancer . Patients Hematopoietic stem cell transplantation ( HSCT ) history include &gt; 1 year transplantation . Refusal consent Individuals , advice Primary enrol physician , may otherwise increase risk adverse reaction venipuncture tuberculin skin test administration . Lymphocytopenia ( &lt; 300 cells/microliter ) Patients known HIV infection . Patients know active tuberculosis include study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Advanced Cancer</keyword>
	<keyword>Solid Tumors</keyword>
	<keyword>Latent Mycobacterium Tuberculosis</keyword>
	<keyword>Tuberculin Skin Test</keyword>
	<keyword>Tuberculosis</keyword>
	<keyword>T-SPOT TB test</keyword>
	<keyword>TB</keyword>
</DOC>